| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4034319 | Vision Research | 2011 | 8 Pages |
PurposeTo evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005% versus placebo.MethodsThis was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00 am and 4:00 pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4 weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis.ResultsSixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6 years) were enrolled. The mean IOP (mm Hg) after latanoprost 0.005% therapy (14.9 ± 3.8) was significantly lower than baseline (18.8 ± 4.7, p < 0.001) or placebo (18.0 ± 4.3), with a mean reduction of −20 ± 13%. Mean PERGLA amplitude (μV) and phase (π-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were similar (p > 0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24 and 1.72 ± 0.23). No significant (p > 0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p > 0.05) associated with PERGLA amplitude or phase.ConclusionTwenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.
Research highlights► First randomized placebo-controlled cross-over clinical trial to examine the relationship between intraocular pressure (IOP) reduction and retinal ganglion cell (RGC) function in glaucoma. ► The mean IOP reduction after latanoprost 0.005% monotherapy was −20% ± 13%. ► RGC function did not show diurnal variation at baseline, latanoprost or placebo session. ► Twenty percent IOP reduction using latanoprost monotherapy was not associated with improvement in RGC function measured using pattern electroretinogram optimized for glaucoma.
